Corcept Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Corcept Therapeutics' es Joseph Belanoff , nombrado en Jan 1999, tiene una permanencia de 25.25 años. compensación anual total es $9.34M, compuesta por 11.6% salario y 88.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.73% de las acciones de la empresa, por valor de $62.90M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 22.5 años, respectivamente.
Información clave
Joseph Belanoff
Chief Executive Officer (CEO)
US$9.3m
Compensación total
| Porcentaje del salario del CEO | 11.6% |
| Permanencia del CEO | 25.3yrs |
| Participación del CEO | 2.7% |
| Permanencia media de la dirección | 3.5yrs |
| Promedio de permanencia en la Junta Directiva | 22.6yrs |
Actualizaciones recientes de la dirección
Recent updates
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Corcept extends distribution agreement for Cushing’s syndrome drug
Sep 23Corcept Therapeutics: A Status Check
Sep 06Corcept cut to Hold at Truist on balanced risk-reward setup
Aug 01Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer
Jun 29I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease
Jun 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
| Sep 30 2019 | n/a | n/a | US$87m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$76m |
| Dec 31 2018 | US$6m | US$680k | US$75m |
| Sep 30 2018 | n/a | n/a | US$152m |
| Jun 30 2018 | n/a | n/a | US$148m |
| Mar 31 2018 | n/a | n/a | US$142m |
| Dec 31 2017 | US$4m | US$647k | US$129m |
Compensación vs. Mercado: La compensación total de Joseph($USD9.34M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Joseph ha aumentado más de un 20% en el último año.
CEO
Joseph Belanoff (66 yo)
25.3yrs
Permanencia
US$9,337,734
Compensación
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 25.3yrs | US$9.34m | 2.72% $ 78.8m | |
| CFO & Treasurer | 3.2yrs | US$3.72m | 0.0092% $ 265.4k | |
| President of Endocrinology | 8.1yrs | US$3.91m | 0.10% $ 2.9m | |
| Chief Development Officer | 2.8yrs | US$3.86m | 0.0058% $ 168.1k | |
| Chief Business Officer & Secretary | 10.3yrs | US$3.96m | 0.044% $ 1.3m | |
| Chief Accounting & Technology Officer | 3.8yrs | sin datos | 0.0070% $ 203.7k | |
| Chief Scientific Officer | 3.8yrs | US$3.11m | 0.090% $ 2.6m | |
| Chief Human Resources & Communications Officer | 2.8yrs | sin datos | sin datos | |
| President of Emerging Markets | less than a year | sin datos | sin datos | |
| President of Oncology | less than a year | sin datos | sin datos |
3.5yrs
Permanencia media
52.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CORT se considera experimentado (3.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 25.3yrs | US$9.34m | 2.72% $ 78.8m | |
| Independent Director | 25.3yrs | US$492.53k | 5.1% $ 147.8m | |
| Independent Director | 19.8yrs | US$509.03k | 1.26% $ 36.6m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman | 25.3yrs | US$1.26m | 2.13% $ 61.7m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.2yrs | US$511.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.7yrs | US$488.53k | 0% $ 0 |
22.6yrs
Permanencia media
67.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CORT son experimentados ( 22.5 años antigüedad media).